<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175847</url>
  </required_header>
  <id_info>
    <org_study_id>RC88-C001</org_study_id>
    <nct_id>NCT04175847</nct_id>
  </id_info>
  <brief_title>A Phase I Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety, Pharmacokinetics and Effect of RC88-ADC For Injection in Subjects With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics and effect of RC88-ADC for injeciton in
      subjects with advanced malignant solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the day of ICF sign to 28 days after the day of the last treatment</time_frame>
    <description>Adverse events was assessed by investigator(s) according to NCI-CTCAE v4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated dose of RC88</measure>
    <time_frame>21 days after first treatment.</time_frame>
    <description>The dose level in which &gt;= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter for total antibody (TAb): Maximum concentration (Cmax)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hour (hr), 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Cmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: Time to maximum concentration (Tmax)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Tmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>AUC will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: Trough concentration (Ctrough)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Ctrough will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: Terminal or apparent terminal half-life (t1/2)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>t1/2 will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for TAb: Systemic clearance (CL)</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>CL will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for antibody-drug conjugate (ADC): Cmax</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Cmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ADC: Tmax</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Tmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ADC: AUC</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>AUC will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ADC: Ctrough</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Ctrough will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ADC: t1/2</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>t1/2 will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for ADC: CL</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>CL will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for Monomethyl Auristatin E (MMAE): Cmax</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Cmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: Tmax</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Tmax will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: AUC</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>AUC will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: Ctrough</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>Ctrough will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: t1/2</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>t1/2 will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter for MMAE: CL</measure>
    <time_frame>Cycle 1 and Cycle 3 (each cycle is 21 days): pre-dose, 0.5 hr, 1 hr, 1.5 hrs, 12 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs, 168 hrs, 240 hrs (and 336 hrs) after start of infusion. Cycle 2: pre-dose.</time_frame>
    <description>CL will be derived from the PK blood samples collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>Cycle 1 to Cycle 3 (each cycle is 21 days): pre-dose, and 336 hrs after start of infusion (cycle 3 only).</time_frame>
    <description>Assessment of anti-RC88 antibodies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>RC88</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC88</intervention_name>
    <description>Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.</description>
    <arm_group_label>RC88</arm_group_label>
    <other_name>RC88 for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary agreement to provide written informed consent.

          -  Male or female, Aged between 18 to 70 years.

          -  Predicted survival ≥ 12 weeks.

          -  Diagnosed with histologically or cytologically-confirmed locally advanced or
             metastatic solid tumors.

          -  Measurable lesion according to RECIST 1.1.

          -  Mesothelin (MSLN) positive as confirmed by the central laboratory. Subject is able to
             provide specimens from primary or metastatic lesions for MSLN tests.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

          -  Adequate organ function, evidenced by the following laboratory results within 7 days
             prior to the study treatment:

          -  Cardiac ejection fraction ≥ 50 %. Hemoglobin ≥ 9g/dL; Absolute neutrophil count ≥
             1.5×10^9 /L Platelets ≥ 100×10^9 /L; Total bilirubin ≤ 1.5× ULN; AST and ALT ≤ 2.5×ULN
             and ≤ 5 x ULN with hepatic metastasis; Serum creatinine ≤1.5×ULN.

          -  All female subjects will be considered to be of child-bearing potential unless they
             are postmenopausal, or have been sterilized surgically.Female subjects of
             child-bearing potential must agree to use two forms of highly effective contraception.
             Male subjects and their female partner who are of child-bearing potential must agree
             to use two forms of highly effective contraception.

          -  Willing to adhere to the study visit schedule and the prohibitions and restrictions
             specified in this protocol.

        Exclusion Criteria:

          -  Known hypersensitivity to the components of RC88-ADC.

          -  Toxicity of previous anti-tumor treatment not recovered to CTCAE Grade 0-1 (with
             exception of Grade 2 alopecia).

          -  Pericardial effusion or cardiac tamponade, or pleural or abdominal effusion with
             clinical symptoms that requires ongoing treatment.

          -  Has a history or current history of explosive, acute, chronic, recurrent or persistent
             myocarditis or pericarditis caused by any cause (eg, virus, tuberculosis, autoimmune
             disease, etc.)

          -  Ophthalmic screening is required: has a history of ocular lesions such as the cornea,
             limbus, conjunctiva, or eyelids (including but not limited to: corneal inflammation,
             corneal dystrophy, dry eye, meibomian gland dysfunction, uveitis, corneal endothelium
             Decompensation, glaucoma, iris corneal endothelial syndrome (ICE), etc.) can not be
             enrolled; has a ophthalmologists-confirmed current medical history of the cornea,
             limbus, conjunctiva, orbital lesions cannot be included;

          -  History of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to
             trial treatment.

          -  History of major surgery within 4 weeks of planned start of trial treatment.

          -  Has received a live virus vaccine within 4 weeks of planned start of trial treatment.

          -  Currently known active infection with HIV or tuberculosis.

          -  Diagnosed with HBsAg , HBcAb positive and HBV DNA copy positive, or HCVAb positive.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  History of other malignancy within the previous 5 years, except for appropriately
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with
             a similar curative outcome as those mentioned above.

          -  known central nervous system metastases.

          -  Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD;

          -  NYHA Class III heart failure

          -  Pregnancy or lactation.

          -  Assessed by the investigator to be unable or unwilling to comply with the requirements
             of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaohong Su, M.D.</last_name>
    <phone>+0810-65391479</phone>
    <email>xiaohong.su@remegen.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suxia Luo, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuguang Zhao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiuwei Cui, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

